Next-generation laser vision correction provides next-day results and recovery1,2 The next-generation ELITATM Fe...
Depression affects nearly 300 million individuals worldwide and does not have a universally effective treatment. The US economic burden as a result of depr...
With a dual-headed probe, the Vscan Air SL offers a sector array and a linear array on a single device which is ideal for switching between focused cardi...
Biobot Analytics, a global leader in wastewater intelligence, announced today that it is launching a Respiratory Illnesses Panel that will include concurre...
WeInfuse, the premier software and technology platform for infusion therapy and medication delivery in the U.S., and NeuroNet...
Value-based care is a holistic, patient-centered healthcare model that focuses on a coordinated effort to help improve patient health outcomes and quality ...
Transaction adds a validated antibody-discovery platform, Phase 2 candidate and royalty stream Company positioned as a leader in next-generation, end-to...
Researchers found that fluid therapy guided by non-invasive and continuous PVi can reduce cardiopulmonary complications and infusion. Masimo (NASD...
Illumina's expansion comes after 16 years of working closely with the company's channel partner in India, Premas Life Sciences. Now with its own permanent ...
TARPEYO is currently approved under accelerated approval to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progr...
3Z, holds expertise in developing genetically engineered models of central nervous system disorders, has successfully identified potential ADHD treatments ...
Complete Integrity Implant System is now fully cleared; targeting launch in Q1-2024 Integrity is highly differentiated by its knitted structure, resulting...
Australia's Monash University and American firm Moderna have announced the establishment of the Monash-Moderna Quantitative Pharmacology Accelerator (MMQPA...
This patent is expected to expire no earlier than June 2035. The allowed claims cover the use of MN-001 (tipelukast) for inhibiting or treating sclero...
© 2025 Biopharma Boardroom. All Rights Reserved.
